What is Endocrine Genetics?
Helping Pharma companies develop Precision medicine using Clinical Data & AI.
What is Endocrine Genetics?
Endocrine Genetics focuses on the role of genetic mutations in disorders affecting the endocrine system, which regulates growth, metabolism, reproduction, and homeostasis through hormone secretion. Advances in genetic testing have transformed the management of these disorders, offering healthcare providers a reliable diagnostic tool—especially when traditional hormone tests yield inconclusive results. GeneHealth’s precision genetic testing helps identify hereditary components to confirm diagnoses, assess familial risks, and significantly improve patient prognosis through early intervention.
Book a Test Now →Common Genetic Endocrine Disorders
| Condition | Pathology & Presentation | Genetic Nuances & Testing Impact |
|---|---|---|
| Congenital Hypothyroidism | Partial or complete loss of thyroid gland function at birth. Thyroid dysgenesis is a common cause (80-85% of cases), while dyshormonogenesis accounts for the rest. | Familial non-goitrous hypothyroidism can lead to intellectual disability and slow growth if untreated. It can also manifest as part of syndromic conditions like Pendred or Bamforth-Lazarus syndrome. |
| Monogenic & Syndromic Obesity | Genetic factors contribute 40-70% to the risk of obesity. Monogenic obesity is severe, early-onset, and associated with endocrine disorders. | Usually due to mutations in the leptin-melanocortin pathway (LEP, LEPR, POMC, PCSK1, MC4R). Can also be syndromic, occurring in Prader-Willi and Bardet-Biedl syndromes. |
| Monogenic Diabetes (MODY & Neonatal) | While Type 1 & 2 are polygenic, monogenic diabetes is caused by single-gene mutations affecting pancreatic beta-cell function. |
MODY: Early onset, autosomal dominant. Often misdiagnosed as Type 1 or 2. Accurate testing enables targeted therapy. Neonatal: Diagnosed under 6 months. Early testing identifies patients who can successfully switch from insulin injections to oral sulfonylureas. |
| Congenital Adrenal Hyperplasia (CAH) | The most common Disorder of Sex Development (DSD). An autosomal recessive group of disorders caused by impaired synthesis of cortisol and aldosterone in the adrenal cortex. | The CYP21A2 gene is the primary target (21-hydroxylase deficiency). Testing requires a two-tier approach (Sequence Analysis followed by Deletion/Duplication testing) due to interference from a highly homologous pseudogene. |
| Androgen Receptor Deficiency (AIS) | Second most common DSD. X-linked recessive disorder where affected males have female external genitalia, blind vagina, and abdominal/inguinal testes. | Pathogenic variants in the AR gene cause Androgen Insensitivity Syndrome (AIS). Next-Generation Sequencing (NGS) successfully detects approximately 95-97% of associated pathogenic variants. |
| Kallmann Syndrome | Characterized by delayed or absent puberty accompanied by an impaired or completely absent sense of smell (anosmia). | The lack of smell clinically distinguishes Kallmann syndrome from other forms of hypogonadotropic hypogonadism. Many patients are completely unaware of their anosmia until formally tested. |
Clinical Applications for Testing
- Ambiguous Genitalia: When patients present with atypical genitalia or discordant gonads, indicating underlying DSDs.
- Growth Concerns: For individuals with short stature or growth abnormalities linked to potential endocrine dysfunction.
- Obesity with Developmental Delays: When severe, early-onset obesity is accompanied by developmental delays, strongly suggesting a monogenic or syndromic genetic basis.
- Family History of Hyperlipidemia: Strong family history pointing to inherited endocrine or metabolic disorders leading to early cardiovascular risks.
- Unexplained Hormonal Issues: For patients whose biochemical hormone tests yield inconclusive results but exhibit clear clinical signs of endocrine imbalance.
Assay Specifications
MLPA: 14 working days.
Why Choose GeneHealth for Endocrine Genetics?
Accurately diagnoses Disorders of Sex Development (like CAH and AIS), allowing for correct gender assignment, psychological support, and tailored medical intervention.
Differentiates monogenic diabetes (MODY/Neonatal) from Types 1 & 2, empowering doctors to transition patients from lifelong insulin to highly effective oral medications.
Utilizes advanced sequencing to navigate highly complex genomic regions (like pseudogene interference in CAH testing) to ensure maximum diagnostic accuracy.
